Medy-Tox Inc. (KOSDAQ:086900)

South Korea flag South Korea · Delayed Price · Currency is KRW
121,300
+8,300 (7.35%)
Mar 5, 2026, 12:20 PM KST
-3.88%
Market Cap 793.23B
Revenue (ttm) 241.80B
Net Income (ttm) 21.84B
Shares Out 7.02M
EPS (ttm) 3,398.79
PE Ratio 33.25
Forward PE 33.15
Dividend 1,200.00 (0.95%)
Ex-Dividend Date Sep 29, 2025
Volume 37,534
Average Volume 47,524
Open 118,900
Previous Close 113,000
Day's Range 116,400 - 121,400
52-Week Range 113,000 - 182,700
Beta 0.32
RSI 29.97
Earnings Date Mar 20, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 718
Stock Exchange KOSDAQ
Ticker Symbol 086900
Full Company Profile

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.

Financial Statements

News

There is no news available yet.